In the context of a section 8 damages action by the Plaintiffs (“Dr. Reddy’s”), Dr. Reddy’s brought a motion under Rule 220 of the Federal Courts Rules, seeking a determination of a question of a law.

The Governor in Council amended the regulations in respect of the PMPRB changing the reference countries used to establish a reasonable price for patented medicines in Canada - adding more European countries, but notably removing the USA and Switzerland. By doing so the Government in effect is seeking to lower patented medicine prices given that Switzerland and the USA have higher than average drug prices.

7299362 Canada owns a trademark registration for ALEXA TRANSLATIONS for consulting services in the field of corporate finance (“Corporate Finance Services”), web development services (“Web Development Services”), and software as a service (SAAS) provider in the field of language translation” (“SAAS Translation Services”), among others.

The appellant, Maoz Betser-Zilevitch (“Mr. Betser”), appealed a decision of the Federal Court (the “Judgment”, 2021 FC 85), dismissing his action against the respondent, PetroChina Canada Ltd. (“PCC”), alleging infringement of his Canadian Patent No. 2,584,627 (the “627 Patent”). Mr. Betser also appealed the decision on costs (the “Costs Judgment,” 2021 FC 151).

Pharamscience Inc. (PMS) is appealing the rejection of its various invalidity attacks on two of Bristol-Myers Squibb’s (BMS) patents – the 2,461,202 patent (202 Patent) and 2,791,171 patent (171 Patent). The 202 Patent specifically claims apixaban, an FXa inhibitor used to treat thromboembolic disorders. The 171 Patent describes a method to formulate apixaban so that it effectively dissolves in vivo.

Janssen Inc. (“Janssen”) markets a prescription medication called OPSUMIT® in Canada for the treatment of pulmonary arterial hypertension (PAH). OPSUMIT® contains the active substance macitentan. Canadian Patent No. 2,659,770 (the “770 Patent”), owned by Actelion Pharmaceuticals Ltd. (“Actelion”), covers the use of macitentan in combination with a phosphodiesterase type-5 inhibitor (PDE5-I) to treat vasoconstriction-related diseases including PAH.

The Plaintiff, Google, brought an action alleging that the Sonos smart speakers infringe Google’s 150 Patent. The 150 Patent relates to a system of echo cancellation and noise suppression in which the order of echo cancellation and noise suppression is adaptively determined based on an amount of noise in the received signal.

Randy River owns a trademark registration for “R2” for shirts and shorts, among others. Osler initiated a section 45 proceeding against this registration. Randy River did not file any evidence of use. As a result, the Registrar expunged the registration. Randy River appealed the Registrar’s decision to the Federal Court of Canada.

In a trademark passing off/infringement proceeding, the plaintiff sought leave to amend its statement of claim to add a new party as a co-defendant and add new infringement allegations.

Mars Canada Inc. (Mars) commenced an action against a number of online retailers – King Tuts Cannabis, West Coast Supply, Shrooms Online, Flash Buds, Sure Buds – alleging that each had sold in Canada THC-infused products in packaging that would likely be confused with Skittles packaging, resulting in consumer confusion and depreciation of goodwill to the brand. Mars sought default judgment against the defendants, other than King Tuts Cannabis.